Literature DB >> 15530663

Galantamine blocks cloned Kv2.1, but not Kv1.5 potassium channels.

Hai-Xia Zhang1, Wei Zhang, Hong-Wei Jin, Xiao-Liang Wang.   

Abstract

Galantamine is a cholinesterase inhibitor (AChEI) currently used in treatment of Alzheimer's disease (AD). In the present study, the effects of galantamine on currents of cloned Kv2.1 and Kv1.5 potassium channels were investigated by using patch-clamp whole cell recording techniques. Kv2.1 and Kv1.5 were stably expressed in HEK293 cells. Galantamine blocked Kv2.1 current in a concentration-dependent manner. When depolarizing from -50 to +40 mV, the IC50 of galantamine for inhibition of Kv2.1 was 5.6 microM. Galantamine 10 microM shifted the activation curve of Kv2.1 to negative potential by 4.0 mV. At the same concentration, galantamine shifted the inactivation curve to negative potential by 25.2 mV. While Kv1.5 was not sensitive to galantamine, Kv1.5 current was not changed by galantamine at concentration of 10 microM. Our data suggest that galantamine potently blocks Kv2.1, but not Kv1.5 channels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15530663     DOI: 10.1016/j.molbrainres.2004.08.010

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  4 in total

1.  Mechanisms of Kv2.1 channel inhibition by celecoxib--modification of gating and channel block.

Authors:  R V Frolov; V E Bondarenko; S Singh
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

Review 2.  The role of intracellular zinc release in aging, oxidative stress, and Alzheimer's disease.

Authors:  Meghan C McCord; Elias Aizenman
Journal:  Front Aging Neurosci       Date:  2014-04-17       Impact factor: 5.750

Review 3.  Does kynurenic acid act on nicotinic receptors? An assessment of the evidence.

Authors:  Trevor W Stone
Journal:  J Neurochem       Date:  2019-11-24       Impact factor: 5.372

4.  SP6616 as a new Kv2.1 channel inhibitor efficiently promotes β-cell survival involving both PKC/Erk1/2 and CaM/PI3K/Akt signaling pathways.

Authors:  T T Zhou; L L Quan; L P Chen; T Du; K X Sun; J C Zhang; L Yu; Y Li; P Wan; L L Chen; B H Jiang; L H Hu; J Chen; X Shen
Journal:  Cell Death Dis       Date:  2016-05-05       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.